1-15 of 15
Jaeyeon Kim
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract CT033: KontRASt-01: A phase Ib/II, dose-escalation study of JDQ443 in patients (pts) with advanced, KRAS G12C-mutated solid tumors

Daniel S. Tan, Toshio Shimizu, Benjamin Solomon, Rebecca S. Heist, Martin Schuler, Maria J. De Miguel Luken, Anas Gazzah, Martin Wermke, Christophe Dooms, Herbert H. Loong, Neeltje Steeghs, Enriqueta Felip, Conor E. Steuer, Eric van Cutsem, Ross A. Soo, Ashley C. Jaeger, Jaeyeon Kim, Kun Xu, Xueying Chen, Xiaoming Cui, Heather Burks, Anna Farago, Philippe A. Cassier
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): CT033.
https://doi.org/10.1158/1538-7445.AM2022-CT033
Published: 15 June 2022
View article titled, Abstract CT033: KontRASt-01: A phase Ib/II, dose-escalation study of JDQ443 in patients (pts) with advanced, KRAS G12C-mutated solid tumors
Journal Articles

Abstract CT197: Phase Ib study of LXH254 + trametinib (TMT) in patients (pts) with NRAS-mutant melanoma

Filippo de Braud, Christophe Dooms, Rebecca S. Heist, Celeste Lebbe, Martin Wermke, David Planchard, Dirk Schadendorf, Piotr Rutkowski, Jürgen Wolf, Paolo A. Ascierto, Ignacio Gil-Bazo, Shumei Kato, Maria Wolodarski, Meredith McKean, Eva Muñoz Couselo, Martin Sebastian, Armando Santoro, Vesselina Cooke, Luca Manganelli, Kitty Wan, Anil Gaur, Tanay S. Samant, Jaeyeon Kim, Giordano Caponigro, Xuân-Mai Couillebault, Michele Moschetta, Adil Daud
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): CT197.
https://doi.org/10.1158/1538-7445.AM2022-CT197
Published: 15 June 2022
View article titled, Abstract CT197: Phase Ib study of LXH254 + trametinib (TMT) in patients (pts) with <em>NRAS</em>-mutant melanoma
Journal Articles

Abstract 2075: Differential tissue clearance results in improved therapeutic index for irinotecan liposome injection (ONIVYDE) when combined with the PARP inhibitor veliparib in preclinical cervical tumors

Alexander Koshkaryev, Jonathan Fitzgerald, Jaeyeon Kim, Ashish Kalra, Walid Kamoun, Sarah Blanchette, Lia Luus, Stephan Klinz, Ozan Alkan, Tad Kornaga, Susan Bates, Yves Pommier, Daryl C. Drummond
Journal: Cancer Research
Cancer Res (2016) 76 (14_Supplement): 2075.
https://doi.org/10.1158/1538-7445.AM2016-2075
Published: 15 July 2016
View article titled, Abstract 2075: Differential tissue clearance results in improved therapeutic index for irinotecan liposome injection (ONIVYDE) when combined with the PARP inhibitor veliparib in preclinical cervical tumors
Journal Articles

Abstract P5-01-06: Characterization of metastatic breast cancer lesions with ferumoxytol MRI and treatment response to MM-398, nanoliposomal irinotecan (nal-IRI)

Jasgit C Sachdev, Ramesh K Ramanathan, Natarajan Raghunand, Jaeyeon Kim, Stephan G Klinz, Eliel Bayever, Jonathan B Fitzgerald, Ronald L Korn
Journal: Cancer Research
Cancer Res (2015) 75 (9_Supplement): P5-01-06.
https://doi.org/10.1158/1538-7445.SABCS14-P5-01-06
Published: 01 May 2015
View article titled, Abstract P5-01-06: Characterization of metastatic breast cancer lesions with ferumoxytol MRI and treatment response to MM-398, nanoliposomal irinotecan (nal-IRI)
Journal Articles

Preclinical Activity of Nanoliposomal Irinotecan Is Governed by Tumor Deposition and Intratumor Prodrug Conversion

Ashish V. Kalra, Jaeyeon Kim, Stephan G. Klinz, Nancy Paz, Jason Cain, Daryl C. Drummond, Ulrik B. Nielsen, Jonathan B. Fitzgerald
Journal: Cancer Research
Series: Author Choice
Cancer Res (2014) 74 (23): 7003–7013.
https://doi.org/10.1158/0008-5472.CAN-14-0572
Published: 30 November 2014
View article titled, Preclinical Activity of Nanoliposomal Irinotecan Is Governed by Tumor Deposition and Intratumor Prodrug Conversion
Open the PDF for Preclinical Activity of Nanoliposomal Irinotecan Is Governed by Tumor Deposition and Intratumor Prodrug Conversion in another window
Includes: Supplementary data
Journal Articles

Abstract A6: Sustained intratumoral activation of MM-398 results in superior activity over irinotecan demonstrated by using a systems pharmacology approach

Jaeyeon Kim, Eliel Bayever, Peter Laivins, Clet Niyikiza, Ulrik Nielsen, Jonathan Fitzgerald, Ashish Kalra, Milind Chalishazar, Stephan Klinz, Nancy Paz, Bart Hendriks, Daryl Drummond, Dmitri Kirpotin, Victor Moyo
Journal: Cancer Research
Cancer Res (2012) 72 (13_Supplement): A6.
https://doi.org/10.1158/1538-7445.CSB12-A6
Published: 06 November 2014
View article titled, Abstract A6: Sustained intratumoral activation of MM-398 results in superior activity over irinotecan demonstrated by using a systems pharmacology approach
Journal Articles

Abstract PR2: A systems biology approach to elucidating the consequences of complex ternary interactions of heparin, FGF ligands, and FGF receptor on downstream signaling in NSCLC cells

Diana H. Chai, Jaeyeon Kim, Jannik Vollmer, Andrijana Radivojevic, Jitendra Kanodia, Marco Muda, Birgit Schoeberl
Journal: Cancer Research
Cancer Res (2012) 72 (13_Supplement): PR2.
https://doi.org/10.1158/1538-7445.CSB12-PR2
Published: 06 November 2014
View article titled, Abstract PR2: A systems biology approach to elucidating the consequences of complex ternary interactions of heparin, FGF ligands, and FGF receptor on downstream signaling in NSCLC cells
Journal Articles

Abstract 2065: Magnetic resonance imaging with an iron oxide nanoparticle demonstrates the preclinical feasibility of predicting intratumoral uptake and activity of MM-398, a nanoliposomal irinotecan (nal-IRI)

Ashish V. Kalra, Joseph Spernyak, Jaeyeon Kim, Arnold Sengooba, Stephan Klinz, Nancy Paz, Jason Cain, Walid Kamoun, Ninfa Straubinger, Yang Qu, Sheryl Trueman, Eliel Bayever, Ulrik Nielsen, Daryl Drummond, Jonathan Fitzgerald, Robert Straubinger
Journal: Cancer Research
Cancer Res (2014) 74 (19_Supplement): 2065.
https://doi.org/10.1158/1538-7445.AM2014-2065
Published: 01 October 2014
View article titled, Abstract 2065: Magnetic resonance imaging with an iron oxide nanoparticle demonstrates the preclinical feasibility of predicting intratumoral uptake and activity of MM-398, a nanoliposomal irinotecan (nal-IRI)
Journal Articles

Abstract 64: A p53 activating mutation drives metastatic high-grade serous ovarian cancer arising from the ovary in mice

Jaeyeon Kim, Donna M. Coffey, Lang Ma, Martin M. Matzuk
Journal: Cancer Research
Cancer Res (2014) 74 (19_Supplement): 64.
https://doi.org/10.1158/1538-7445.AM2014-64
Published: 01 October 2014
View article titled, Abstract 64: A p53 activating mutation drives metastatic high-grade serous ovarian cancer arising from the ovary in mice
Journal Articles

Abstract A41: Sustained intratumoral activation of MM-398 results in superior activity over irinotecan demonstrated by using a systems pharmacology approach.

Jaeyeon Kim, Eliel Bayever, Peter Laivins, Clet Niyikiza, Ulrik Nielsen, Jonathan Fitzgerald, Ashish Kalra, Milind Chalishazar, Stephan Klinz, Nancy Paz, Bart Hendriks, Daryl Drummond, Dmitri Kirpotin, Victor Moyo
Journal: Cancer Research
Cancer Res (2012) 72 (14_Supplement): A41.
https://doi.org/10.1158/1538-7445.PANCA2012-A41
Published: 03 April 2014
View article titled, Abstract A41: Sustained intratumoral activation of MM-398 results in superior activity over irinotecan demonstrated by using a systems pharmacology approach.
Journal Articles

Abstract A63: MM-398/PEP02, a novel liposomal formulation of irinotecan, demonstrates stromal-modifying anticancer properties.

Nancy Paz, Peter Laivins, Clet Niyikiza, Ulrik Nielsen, Jonathan Fitzgerald, Ashish Kalra, Milind Chalishazar, Stephan Klinz, Jaeyeon Kim, Daryl Drummond, Dmitri Kirpotin, Victor Moyo, Eliel Bayever
Journal: Cancer Research
Cancer Res (2012) 72 (14_Supplement): A63.
https://doi.org/10.1158/1538-7445.PANCA2012-A63
Published: 03 April 2014
View article titled, Abstract A63: MM-398/PEP02, a novel liposomal formulation of irinotecan, demonstrates stromal-modifying anticancer properties.
Journal Articles

Abstract 5622: The tumor microenvironment modulates the delivery and activation of liposomal encapsulated irinotecan, MM-398.

Ashish Kalra, Jaeyeon Kim, Stephan Klinz, Nancy Paz, Joseph Reutt, Daryl Drummond, Dmitri Kirpotin, Victor Moyo, Eliel Bayever, Peter Laivins, Clet Niyikiza, Ulrik Nielsen, Jonathan Fitzgerald
Journal: Cancer Research
Cancer Res (2013) 73 (8_Supplement): 5622.
https://doi.org/10.1158/1538-7445.AM2013-5622
Published: 15 April 2013
View article titled, Abstract 5622: The tumor microenvironment modulates the delivery and activation of liposomal encapsulated irinotecan, MM-398.
Journal Articles

Abstract 328: A p53 activating mutation accelerates the progression of high-grade serous ovarian cancer arising from the fallopian tube.

Jaeyeon Kim, Donna M. Coffey, Lang Ma, Martin M. Matzuk
Journal: Cancer Research
Cancer Res (2013) 73 (8_Supplement): 328.
https://doi.org/10.1158/1538-7445.AM2013-328
Published: 15 April 2013
View article titled, Abstract 328: A p53 activating mutation accelerates the progression of high-grade serous ovarian cancer arising from the fallopian tube.
Journal Articles

Abstract 4878: The fallopian tube is the origin of high-grade serous ovarian carcinomas in a mouse model

Jaeyeon Kim, Donna M. Coffey, Chad J. Creighton, Zhifeng Yu, Shannon M. Hawkins, Martin M. Matzuk
Journal: Cancer Research
Cancer Res (2012) 72 (8_Supplement): 4878.
https://doi.org/10.1158/1538-7445.AM2012-4878
Published: 15 April 2012
View article titled, Abstract 4878: The fallopian tube is the origin of high-grade serous ovarian carcinomas in a mouse model
Journal Articles

Abstract 5696: Evaluating determinants for enhanced activity of MM-398/PEP02; a novel nanotherapeutic encapsulation of irinotecan (CPT-11)

Ashish Kalra, Stephan Klinz, Nancy Paz, Jaeyeon Kim, Milind Chalishazar, Daryl Drummond, Dmitri Kirpotin, Victor Moyo, Clet Niyikiza, Jonathan Fitzgerald
Journal: Cancer Research
Cancer Res (2012) 72 (8_Supplement): 5696.
https://doi.org/10.1158/1538-7445.AM2012-5696
Published: 15 April 2012
View article titled, Abstract 5696: Evaluating determinants for enhanced activity of MM-398/PEP02; a novel nanotherapeutic encapsulation of irinotecan (CPT-11)